Vinstar Biotech

Vinstar Biotech is a clinical-stage biopharmaceutical company based in Guangzhou, China, dedicated to discovering and developing innovative small molecule drugs for metabolic diseases. The company's primary focus is on non-alcoholic steatohepatitis (NASH), now commonly referred to as MASH, and other metabolic disorders with significant unmet medical needs. Its lead program, VS-101, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 2 clinical trials. Vinstar utilizes a structure-based drug discovery platform to optimize the potency and selectivity of its candidates. The company aims to provide effective and safe therapeutic options for patients suffering from chronic metabolic conditions globally. Vinstar is supported by prominent life science investors and maintains operations in both China and the United States.